Ideas to Action:

Independent research for global prosperity

X

Global Health Policy Blog

Feed

AERASThe Aeras Global TB Vaccine Foundation of Bethesda, MD and The University of California, Los Angeles (UCLA) announced today that the two organizations had executed a non-exclusive license for a tuberculosis vaccine technology developed at UCLA.

Under the agreement, UCLA is providing Aeras with a non-exclusive license to develop and market UCLA's rBCG30 tuberculosis vaccine technology for use in the developing world. Aeras is a nonprofit organization dedicated to developing new TB vaccines and distributing them to people in areas of the world hardest hit by the disease.

Related Topics:

Disclaimer

CGD blog posts reflect the views of the authors drawing on prior research and experience in their areas of expertise. CGD does not take institutional positions.